DNA Polymerase Technology

DNA Polymerase Technology is a private, revenue-generating company focused on engineering superior DNA polymerases for PCR. The company's core technology involves proprietary mutations to Taq DNA polymerase, creating enzymes with enhanced properties like inhibitor resistance, speed, and reverse transcriptase activity. It has a strong history of SBIR/STTR grant funding, validating its R&D focus, and commercializes products directly to researchers and diagnostic developers. Its market position is built on solving specific, persistent pain points in molecular biology and applied testing.

Proprietary protein engineering platform for creating genetically-modified DNA polymerases with enhanced properties such as inhibitor resistance (blood, soil), reverse transcriptase activity, high speed, and improved fidelity.

DPT competes in the PCR enzyme market against giants like Thermo Fisher Scientific, Qiagen, and New England Biolabs. Its competitive advantage is not breadth but depth—offering superior performance in specific, challenging applications (e.g., direct-from-blood PCR) where standard enzymes fail, rather than competing across the entire portfolio of molecular biology reagents.